iHub News
4月前
Quoin advances QRX003 development after positive FDA meeting on Netherton syndromeMarch 25, 2026 11:07 AM
IH Market News
Quoin Pharmaceuticals (NASDAQ:QNRX) said it received encouraging regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type C meeting held on March 25, 2026 regarding the development of QRX003, its investigational treatment for Netherton syndrome, a rare genetic skin disorder.According to the company, the FDA indicated that a single Phase 3 trial could be sufficient to support a future marketing application for QRX003, rather than the two Phase 3 studies the company had previously considered necessary. Regulators also signaled openness to alternative clinical trial designs, including approaches that may not require a traditional placebo or vehicle-controlled study at the outset.Based on the feedback, Quoin said it plans to submit data from its ongoing Phase 2 and pediatric investigator-led studies, while preparing to launch a pivotal Phase 3 program. The company aims to complete patient recruitment by the end of 2026 and could potentially file a New Drug Application (NDA) in 2027.“We are very pleased to provide this update from our recent Type C meeting with FDA. Importantly, FDA acknowledged that a single Phase 3 study may be sufficient to support U.S. marketing approval of QRX003 for Netherton Syndrome, rather than the two Phase 3 studies the Company had originally contemplated. With our established network of U.S. and EU clinical trial sites, we are confident that we will be in a position to initiate our pivotal Phase 3 program and fully complete recruitment this year. FDA also expressed openness to an alternative, innovative clinical trial design, such as a randomized withdrawal or randomized delayed start study, which may be more appropriate Phase 3 design in the setting of Netherton Syndrome than a traditional upfront randomized, controlled study. Overall, this meeting represents an important milestone for Quoin and the Netherton Syndrome community at large. We are now in a position to move forward with clarity, and we remain on track to advance development of QRX003 with the goal of potentially delivering the first approved medication for the treatment of Netherton Syndrome. Finally, I would like to sincerely thank each of the KOLs who participated in the meeting: Professor Alan Irvine, Dr. Amy Paller, Dr. Keith Choate, Professor Jemima Mellerio, Professor Anna Martinez, Professor James Halpern and Professor Suzanne Pasmans. We are truly grateful for your continued support and expert input.” said Dr. Michael Myers, CEO of Quoin Pharmaceuticals.
Key outcomes from the FDA meeting
The company highlighted two main takeaways from its discussions with regulators:The FDA suggested that a single Phase 3 clinical study may be adequate to support U.S. marketing approval of QRX003 for Netherton syndrome.
Regulators showed openness to alternative trial designs, such as randomized withdrawal or randomized delayed-start studies, which may better suit research in rare diseases and may not require a traditional placebo or vehicle-controlled design at the start.Following the meeting, Quoin said it is implementing the FDA’s recommendations to prepare for the next stage of development. The company plans to request another regulatory meeting to review the Phase 2 and pediatric data before formally initiating the Phase 3 program.If the development timeline proceeds as planned, Quoin expects to complete enrollment in the Phase 3 study by the end of 2026, potentially enabling the company to seek FDA approval for QRX003 in 2027. The therapy could become the first approved treatment specifically for Netherton syndrome.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. is a late-stage clinical specialty pharmaceutical company focused on developing treatments for rare and orphan diseases. The company’s pipeline includes therapies targeting conditions such as Netherton syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma, and other rare disorders.Quoin said its goal is to address significant unmet medical needs faced by patients with rare diseases, along with their families and healthcare providers.Quoin Pharmaceuticals stock price
Original: Quoin advances QRX003 development after positive FDA meeting on Netherton syndrome
subslover
9月前
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others
ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new healthcare focused institutional investors with the potential to raise up to $104.5 million in gross proceeds, including initial upfront funding of $16.5 million and up to an additional $88.0 million upon the potential cash exercise of accompanying warrants at the election of the investors. The private placement was priced at a premium to the Company’s prior day’s closing stock price.
The financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others.
Maxim Group LLC is acting as sole placement agent for the private placement.
Pursuant to terms of the securities purchase agreement, Quoin will issue an aggregate of 1,993,940 American Depository Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to an aggregate of 7,975,760 ADSs, at a combined purchase price of $8.25 per ADS and accompanying warrants, in accordance with the "Minimum Price" requirement as defined in the Nasdaq rules. The accompanying warrants will consist of four tranches:
Series H warrants to purchase up to 1,993,940 ADSs at an exercise price of $9.075 per ADS for an aggregate exercise price of up to $18.1 million. The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Company’s public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.
Series I warrants to purchase up to 1,993,940 ADSs at an exercise price of $10.3125 per ADS for an aggregate exercise price of up to $20.6 million. The Series I warrants are immediately exercisable and expire as follows: 50% of the Series I warrants will expire on the earlier of (i) 30 days after the Company’s public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance; and the remaining 50% of Series I warrants will expire on the earlier of (i) 30 days after the Company’s public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.
Series J warrants to purchase up to 1,993,940 ADSs at an exercise price of $12.375 per ADS for an aggregate exercise price of up to $24.7 million. The Series J warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.
Series K warrants to purchase up to 1,993,940 ADSs at an exercise price of $12.375 per ADS for an aggregate exercise price of up to $24.7 million. The Series K warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the Company’s sale of a Priority Review Voucher (PRV) and (ii) five years from the date of issuance.
In lieu of ADSs, certain investors are purchasing pre-funded warrants at a combined purchase price of $8.2499 per pre-funded warrant and accompanying warrants, which equals the purchase price per ADS and accompanying warrants less $0.0001, which is in turn equal to the exercise price of each pre-funded warrant. The private placement is expected to close on or about October 14, 2025 subject to satisfaction of customary closing conditions.
Quoin intends to use the upfront net proceeds from the private placement for general corporate purposes, which may include operating expenses, research and development, including completion of clinical development of QRX003 for Netherton Syndrome, working capital, future acquisitions and general capital expenditures. The aggregate net proceeds (assuming the cash exercise of all accompanying warrants) are expected to be sufficient to fund the Company into 2027.
The offer and sale of the foregoing securities, including the ADSs, pre-funded warrants, and accompanying common warrants, are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the ADS purchased in the private placement and the ADS underlying the warrants.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises three products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “look forward to,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the Company’s ability to consummate the closing of the offering when intended and the intended use of proceeds, the Company’s ability to satisfy closing conditions for the offering, the filing of a registration statement with the Securities and Exchange Commission registering the resale of the ADS purchased in the private placement and the ADS underlying the warrants, whether or when the Company may receive Type C meeting minutes from the FDA and the content thereof, whether or when th
subslover
1年前
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to Baseline
Key endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index (CDLQI) all demonstrated improvement from baseline
QRX003 is being well tolerated and no adverse events have been reported
Patient is expected to continue to be treated with QRX003 to assess progress
Company continues to advance QRX003 in its late-stage Netherton Syndrome clinical studies
ASHBURN, Va., May 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study.
As the table below illustrates, after 12 weeks of treatment, clear evidence of skin healing in the area treated with QRX003 compared to baseline was observed.
End Point Baseline 12 weeks
(End of treatment period)
M-IASI* 36 12
IGA** 4 (Severe) 2 (Mild)
CDQLI*** 19 11
*M-IASI: Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement.
**IGA: Investigator’s Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the overall severity of disease symptoms.
*** CDQLI: The Children’s Dermatology Life Quality Index is a validated clinical tool designed for children aged 4-15 that is used to measure the impact of their skin disease on a child’s quality of life in terms of symptoms, leisure activities, sleep, school, personal relationship and treatment. The scale for the CDQLI is 0-30.
QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial results, the patient is expected to continue to be treated with QRX003 with a further clinical assessment by the investigator scheduled after 24 weeks of treatment.
Quoin CEO, Dr. Michael Myers, said, “We are very pleased to announce such positive initial data across a number of clinical endpoints for the pediatric subject in this study, which we believe may be the first formal clinical study for this disease. The two grade improvement, which is accepted as being clinically meaningful in both the Investigator’s Global Assessment (IGA) (severe to mild) and the M-IASI (moderate to clear) after 12 weeks of QRX003 application is very encouraging. We fully support the investigator’s decision to continue treatment. In addition, the validated CDQLI questionnaire results to date indicate that the pediatric subject in the study is experiencing a distinct positive improvement in their quality of life as a result of ongoing treatment with QRX003. Consistent with what we are observing in our Netherton Syndrome studies, QRX003 is well tolerated with no adverse events reported. We look forward to expanding this study to include additional pediatric subjects in other countries and to advancing the clinical development of the product for this disease. There is currently no approved treatment or cure for peeling skin syndrome and there are no clinical studies listed on clinicaltrials.gov as actively recruiting and dosing subjects, thus presenting a further opportunity for Quoin to potentially achieve the first regulatory approval for another rare genetic disease. We are also continuing to advance QRX003 in our late-stage Netherton Syndrome clinical studies."
About Peeling Skin Syndrome (PSS)Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS, and patients try to manage symptoms using over-the-counter emollients.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looki
subslover
1年前
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks Treatment
High Durability of Treatment Effect of QRX003 with Continuous Daily Dosing
Patient Continues Not to Require Previously Necessary Medications
With Patient’s Pruritus Almost Completely Eliminated, Patient Continues to Experience Zero Nightly Sleep Disturbance
No Adverse Events Reported from 6 Weeks of Whole Body Treatment with QRX003
Approval Received to Initiate Whole Body Testing of a Second Pediatric Patient
ASHBURN, Va., April 02, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application of QRX003, the subject’s skin remains almost completely healed demonstrating the durability of ongoing daily treatment with the product. In addition, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids. Importantly, with the patient’s pruritus or itch almost completely eliminated, she continues to experience zero nightly sleep disturbances without the need for any sedating medication, marking the first continuous period of uninterrupted sleep in the patient’s life. No adverse events have been reported to date after 6 weeks of whole body treatment with QRX003.
Quoin CEO Dr. Michael Myers, said, “As we continue to monitor the progress of this first patient to receive whole body application with QRX003, we are very pleased to announce that after 6 weeks of dosing we are seeing continued positive improvement and the patient’s skin is almost completely healed now. The patient continues to remain off previously needed medications including antihistamines, antivirals, and glucocorticoids, and she has not needed any antibiotics in the 6 weeks since the initiation of dosing with QRX003. Very importantly also, with her pruritus almost completely eliminated, the patient is still experiencing zero nightly sleep disturbances without the need for any sedating medications. For a majority of Netherton Syndrome patients, the continuous presence of chronically debilitating pruritus is the worst symptom of this disease and it severely impacts their ability to sleep or to even sit still for any period of time. Often heavy sedation is required to allow patients to sleep and sit still, which in turn has a major negative impact on their quality of life. The almost complete healing of the skin and the elimination of this chronically debilitating pruritus provides strong clinical evidence that QRX003 is successfully tackling the root causes of this disease and not merely providing symptomatic relief. Furthermore, I am very pleased to report that no adverse events have been reported after six full weeks of whole-body application of QRX003. Based on these positive results, approval has been received to initiate whole body application of QRX003 to a second pediatric Netherton patient. Testing is expected to commence in just a few weeks and we look forward to providing updates on both patients progress as we continue with our plans to further expand this study to include additional pediatric subjects.”
subslover
1年前
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Groundbreaking data from first whole body application of QRX003 underscores potential efficacy
Transformational improvement in disease state after just 2 weeks of treatment
Clear visual evidence of skin healing observed
Improvement has eliminated need for previously required medications
Patient is now experiencing zero nightly sleep disturbance for the first time
No adverse events reported from whole body treatment
ASHBURN, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. Dramatic improvement was observed in the patient’s disease state with clear visual evidence of skin healing observed after just two weeks of whole-body application of QRX003. No adverse events have been reported to date.
Both key clinical endpoints, Investigator’s Global Assessment (IGA) and Pruritus or itch, demonstrated highly significant clinical improvements from baseline after two weeks of treatment with QRX003 on patient’s whole body.
Table 1: Results for First Pediatric Patient Receiving QRX003 ‘Whole-Body’ Application
Endpoint* Baseline Two Week
Investigator Global Assessment 7 1-2
Pruritus 5 1
*Both IGA and Pruritus scores based on a 0-10 scale.
Furthermore, following treatment with QRX003, the patient has now discontinued previously required medications including all antihistamines, glucocorticoids and antivirals. Importantly, the patient has not needed treatment with any antibiotics since the whole-body application of QRX003 was initiated. In addition, the patient is now experiencing zero nightly sleep disturbances for the first time in her life. No adverse events have been reported to date.
Quoin CEO Dr. Michael Myers, said, “While cautioning upfront that this data is from just a single patient over a short period of time, these truly exciting and groundbreaking results provide a snapshot of the potential efficacy of QRX003 as a chronic whole-body treatment of Netherton Syndrome. After just two weeks of treatment, a transformational life change has occurred for this first patient to receive whole-body application of QRX003. At baseline, the Investigators Global Assessment, or IGA, for the patient’s skin was at 5 on a scale of 0-10. After two weeks of treatment with QRX003, the IGA was at 1, representing an almost complete elimination of the visual effects of the disease on the patient’s skin. In addition, her pruritus, which at baseline was described as “chronically debilitating itch” and a 7 on of a scale of 0-10, had significantly dropped to a “highly tolerable and non-intrusive” score of between 1 and 2 after only two weeks of treatment with QRX003. Even more encouraging is the fact that the patient has been able to discontinue ongoing treatment with a variety of previously required medications including antihistamines, antivirals, glucocorticoids and she has not needed any antibiotics since the initiation of dosing with QRX003. We believe that these results indicate that QRX003 is directly targeting the root cause of the disease and has the potential to provide NS patients with the opportunity to have lives essentially free from the ravages of this terrible disease. In addition, the patient is now, for the first time, experiencing zero nightly sleep disturbances, again providing additional evidence of the potential efficacy of QRX003. Finally, we are very pleased to report that no adverse events have been recorded after two weeks of twice-daily, whole-body application of QRX003. As we continue with our plans to expand this study to include additional pediatric subjects in other countries who would also receive whole body application of QRX003, we believe that the highly encouraging nature of the results generated to date for this patient could potentially bring hope and comfort to children and families whose lives are being so dramatically impacted by the consequences of this cruel disease.”
About Netherton Syndrome
Netherton Syndrome, a form of Ichthyosis, is a rare hereditary skin disorder caused by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Type 5) that leads to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma, and eczema. Patients often suffer from severe dehydration, chronic skin inflammation and stunted growth. Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.
subslover
1年前
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment.
Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome. Netherton Syndrome is a hereditary disorder affecting the skin, hair, and immune system, currently lacking an approved treatment or cure. Quoin is responsible for obtaining all FDA and other regulatory body approvals necessary to market the products in the US and other countries. Upon the successful completion of FDA or EU approval, Skinvisible is entitled to receive a milestone payment of $5 million and ongoing royalties from sales.
LICENSEE CLINICAL AND REGULATORY SUCCESS:
Skinvisible's licensee, Quoin Pharmaceuticals, Inc. (NASDAQ:QNRX) reported multiple positive developments for QRX003, which utilizes Skinvisible's Invisicare technology and its formulation for the rare skin disease: Netherton Syndrome:
Key Recent Developments:
FDA clearance for Netherton Syndrome "whole body" study at Northwestern University
Significant clinical improvements in both open label and pediatric studies including subject's disease classification improved from "severe" to "mild" after 6 weeks dosing
No adverse events or safety concerns reported to date from each of Quoin's ongoing clinical studies in Netherton Syndrome subjects
International expansion of studies to UK, Ireland, and Saudi Arabia
Netherton Syndrome product QRX003 with Invisicare delivery technology licensed in 60 countries
"We anticipate a significant milestone with our licensee potentially receiving the first FDA approval for a formulation using our Invisicare delivery technology," said Terry Howlett, President and CEO of Skinvisible. "This validates our strategy of developing innovative topical and transdermal therapeutics for other indications. As our licensee advances their clinical trials, we remain committed to supporting their efforts to bring this groundbreaking treatment to Netherton Syndrome patients worldwide."
Along with its ongoing research and development, Skinvisible continues to actively seek strategic partnerships with pharmaceutical and biotech companies to bring topical and transdermal Invisicare formulations to the market including the first transdermal obesity therapies and explore broader applications of its delivery platform with other small molecules.
For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please contact info@skinvisible.com.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
glenn1919
8月前
ErnieBilco
9月前
makinezmoney
9月前
JJ8
1年前
XenaLives
2年前
TrendTrade2016
2年前
BEIJING BILL
2年前
81vette
2年前
Disquisition
2年前
Monksdream
2年前
Stock_Gambit
2年前
メールアドレスで登録
